AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
Key Takeaways
- Johnson & Johnson secured FDA clearance for Icotyde, an oral plaque psoriasis medication created with Protagonist Therapeutics (PTGX), triggering a ~4.69% decline in ABBV shares
- The once-daily pill positions itself as a direct challenger to AbbVie’s critical immunology asset, Skyrizi
- Wall Street forecasts remain optimistic, expecting Skyrizi revenue to climb 23% through FY2026 despite emerging competition
- Technical indicators show ABBV trading beneath key moving averages: SMA-20 ($227.73), SMA-50 ($224.27), and hovering near SMA-200 ($214.95), signaling bearish momentum
- Management laid out FY2026 earnings guidance between $14.37–$14.57 per share while launching a strategic antibody development alliance with Alloy Therapeutics
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s session following regulatory approval from the FDA for Johnson & Johnson’s (JNJ) plaque psoriasis therapy, Icotyde. The development shook investor confidence as Skyrizi represents a cornerstone of AbbVie’s growth strategy in the post-Humira era.
AbbVie Inc., ABBV
Created through a partnership between J&J and Protagonist Therapeutics (PTGX), Icotyde offers patients a convenient once-daily oral option for treating plaque psoriasis. This formulation places it squarely in competition with Skyrizi, which stands as AbbVie’s leading immunology franchise and a crucial revenue generator.
Despite the competitive headwinds, Wall Street analysts maintain confidence in Skyrizi’s outlook. The medication’s strong efficacy data and flexible dosing schedule continue to be viewed as competitive differentiators, with revenue forecasts showing a robust 23% expansion through FY2026.
ABBV settled near $212.50 after starting the session below the previous close of $218.60. Intraday trading established a range between $209.42 and $218.60, demonstrating sustained downward pressure throughout the session.
Chart Analysis Points to Weakness
From a technical perspective, ABBV has fallen beneath three critical moving averages: the SMA-20 at $227.73, SMA-50 at $224.27, and now trades marginally below the SMA-200 at $214.95. This configuration across all major timeframes signals deteriorating technical strength.
Momentum indicators across both daily and weekly timeframes have entered oversold territory based on RSI readings. The CCI and BBP metrics confirm negative momentum and oversold conditions. Meanwhile, ADX readings remain subdued, indicating the absence of a defined trending environment, while MACD maintains a neutral posture.
Immediate downside support materializes at $210.83, where a decisive breakdown could accelerate selling pressure. Overhead resistance emerges at the Ichimoku Kijun level of $227.58.
Traders are monitoring a potential range-bound scenario between $210.83 and $215.22, with tactical opportunities potentially emerging near the lower boundary if price action consolidates.
The stock’s 200-day simple moving average at $214.95 might provide temporary support, though the preponderance of technical evidence currently favors sellers.
Legacy Drug Challenges and Aesthetic Headwinds
The competitive pressure from Icotyde arrives during a challenging transition period for AbbVie. The pharmaceutical giant continues navigating the aftermath of Humira’s patent expiration, while simultaneously contending with persistent weakness in its aesthetics division, particularly products like Juvederm.
Recent regulatory filings reveal that several institutional investors have reduced their ABBV holdings, mirroring broader sentiment shifts around the company’s near-term prospects. Corporate insider trading activity has tilted exclusively toward selling, with two transactions recorded over the past quarter and zero purchases.
On a constructive note, AbbVie unveiled a long-term strategic collaboration with Alloy Therapeutics focused on building an enhanced antibody discovery platform. The arrangement features initial payments and performance-linked milestones, demonstrating ongoing commitment to pipeline development.
Company leadership also provided FY2026 earnings per share guidance ranging from $14.37 to $14.57, which management frames as evidence of confidence in the organization’s fundamental business trajectory.
Wall Street’s consensus price target reaches $251.44, accompanied by a recommendation score of 2.2 — indicating moderate buy sentiment. Institutional investors control 74.71% of outstanding shares.
According to GF Value metrics, ABBV carries an estimated fair value of $198.80, positioning current trading levels within reasonable valuation parameters.
The post AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment appeared first on Blockonomi.
You May Also Like
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC
Trending: Not Wrong, Bob Lazar’s Alien Claims Vindicated as White House Registers Aliens.gov Domain
